The JPT1 antibody is a research tool designed to target the JADE1 (Jade family PHD zinc finger 1) protein, a component of the HBO1 (histone acetyltransferase binding to ORC1) complex. JADE1 is implicated in epigenetic regulation, particularly through histone H4 acetylation, which influences chromatin remodeling, gene transcription, and DNA repair. It plays roles in cell cycle progression, apoptosis, and organogenesis, with links to cancers, polycystic kidney disease, and hypoxia responses. The JPT1 antibody, often used in techniques like Western blotting, immunoprecipitation, and immunofluorescence, helps elucidate JADE1’s interaction networks and its regulatory mechanisms in development and disease. Studies using this antibody have highlighted JADE1’s tumor-suppressive functions and its role in modulating Wnt/β-catenin signaling. Researchers rely on JPT1 to investigate how JADE1 dysfunction contributes to pathological states, offering insights into therapeutic targeting of epigenetic pathways. Validation specifics (e.g., species reactivity, applications) vary by commercial source, requiring careful experimental optimization.